Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBT of -$184.0 million for Q1 2026, down 22.67% year-over-year from -$237.9 million in Q1 2025, and down 44.1% on a QoQ basis from -$127.7 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of EBT data on file, last reported at -$184.0 million in Q1 2026.
- Quarterly EBT fell 22.67% year-over-year to -$184.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$605.2 million (down 3829.31% YoY) and the FY2025 annual result came in at -$571.0 million, down 14175.0% from the prior year.
- EBT declined to -$184.0 million in Q1 2026 per RARE's latest filing, from -$127.7 million in the prior quarter.
- Across five years, EBT topped out at $430.2 million in Q4 2024 and bottomed at -$238.8 million in Q3 2022.
- The 5-year median for EBT is -$153.3 million (2022), against an average of -$121.8 million.
- The widest annual swing landed in 2022, when EBT sank 227.98%; it then soared 437.59% in 2024.
- Tracing RARE's EBT over 5 years: stood at -$153.3 million in 2022, then grew by 16.87% to -$127.4 million in 2023, then soared by 437.59% to $430.2 million in 2024, then sank by 129.68% to -$127.7 million in 2025, then slumped by 44.1% to -$184.0 million in 2026.
- Per Business Quant, the three latest RARE EBT figures stand at -$184.0 million (Q1 2026), -$127.7 million (Q4 2025), and -$179.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -184.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -184.00 Mn |
| Dec 31, 2025 | -127.69 Mn |
| Sep 30, 2025 | -179.54 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Mar 31, 2025 | -150.00 Mn |
| Dec 31, 2024 | 430.18 Mn |
| Sep 30, 2024 | -133.21 Mn |
| Jun 30, 2024 | -130.74 Mn |
| Mar 31, 2024 | -170.23 Mn |
| Dec 31, 2023 | -127.43 Mn |
| Sep 30, 2023 | -159.00 Mn |
| Jun 30, 2023 | -159.10 Mn |
| Mar 31, 2023 | -163.48 Mn |
| Dec 31, 2022 | -153.28 Mn |
| Sep 30, 2022 | -238.82 Mn |
| Jun 30, 2022 | -157.86 Mn |
| Mar 31, 2022 | -151.76 Mn |
| Dec 31, 2021 | -124.77 Mn |
| Sep 30, 2021 | -72.82 Mn |
| Jun 30, 2021 | -121.97 Mn |
| Mar 31, 2021 | -135.76 Mn |
| Dec 31, 2020 | -23.94 Mn |
| Sep 30, 2020 | -68.53 Mn |
| Jun 30, 2020 | 25.73 Mn |
| Mar 31, 2020 | -118.62 Mn |
| Dec 31, 2019 | -91.24 Mn |
| Sep 30, 2019 | -112.70 Mn |
| Jun 30, 2019 | -98.96 Mn |
| Mar 31, 2019 | -96.54 Mn |
| Dec 31, 2018 | -87.70 Mn |
| Sep 30, 2018 | -87.06 Mn |
| Jun 30, 2018 | -52.63 Mn |
| Mar 31, 2018 | 30.29 Mn |
| Dec 31, 2017 | -97.95 Mn |
| Sep 30, 2017 | -79.22 Mn |
| Jun 30, 2017 | -72.88 Mn |
| Mar 31, 2017 | -68.29 Mn |
| Dec 31, 2016 | -71.25 Mn |
| Sep 30, 2016 | -64.91 Mn |
| Jun 30, 2016 | -56.92 Mn |
| Mar 31, 2016 | -52.64 Mn |
| Dec 31, 2015 | -55.24 Mn |
| Sep 30, 2015 | -39.26 Mn |
| Jun 30, 2015 | -29.69 Mn |
| Mar 31, 2015 | -21.23 Mn |
| Dec 31, 2014 | -16.75 Mn |
| Sep 30, 2014 | -15.66 Mn |
| Jun 30, 2014 | -13.59 Mn |
| Mar 31, 2014 | -13.63 Mn |
| Dec 31, 2013 | -9.47 Mn |
| Sep 30, 2013 | -7.69 Mn |
| Jun 30, 2013 | -8.65 Mn |
| Mar 31, 2013 | -6.76 Mn |